New national advice has recommended puberty blockers remain a clinical option for certain children with gender dysphoria.
The medication has been the subject of fierce debate and is restricted in parts of Australia and overseas.
The advice is now open for public consultation with the full national guidelines due in 2028.
Puberty blockers should remain a clinical option for certain trans and gender diverse children, despite low-certainty evidence about their benefits and harms, according to long-awaited national advice.
The National Health and Medical Research Council (NHMRC) interim advice could have significant policy implications for the Queensland and Northern Territory governments, which have banned or restricted puberty blockers in the public system.
Gonadotropin-releasing hormone analogues (GnRHa) or puberty blockers, are injections that pause aspects of physical development by suppressing sex hormones.
They are a form of medical intervention prescribed to children with gender incongruence, a clinical term for a difference between a person's gender and their sex recorded at birth.
Some people with gender incongruence also experience distress, which is known as gender dysphoria.
Advocates argue pausing puberty temporarily buys patients time to decide if they want to take the next steps towards transitioning with hormones like oestrogen or testosterone. However critics say the medication is experimental and potentially dangerous.